CALGB 150905 (Alliance): Rituximab broadens the anti-lymphoma response by activating unlicensed NK cells

Natural killer (NK) cells contribute to clinical responses in patients treated with rituximab, but the rules determining NK cell responsiveness to mAb therapies are poorly defined. A deeper understanding of the mechanisms responsible for antibody-dependent cellular cytotoxicity (ADCC) could yield us...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Immunol Res
Hlavní autoři: Du, Juan, Lopez-Verges, Sandra, Pitcher, Brandelyn N., Johnson, Jeffrey, Jung, Sin-Ho, Zhou, Lili, Hsu, Katharine, Czuczman, Myron S., Cheson, Bruce, Kaplan, Lawrence, Lanier, Lewis L., Venstrom, Jeffrey M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4264658/
https://ncbi.nlm.nih.gov/pubmed/24958280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-13-0158
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky